z-logo
Premium
Is Type 1 Diabetes in the Japanese Population the Same as among Caucasians?
Author(s) -
KAWASAKI EIJI,
EGUCHI KATSUMI
Publication year - 2004
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1196/annals.1337.014
Subject(s) - type 2 diabetes , population , medicine , diabetes mellitus , demography , environmental health , endocrinology , sociology
A bstract : In the Japanese population, the incidence of type 1 diabetes is as low as ∼2 cases/year/100,000 children, which is much lower compared to that in countries with populations predominantly of Caucasian origin. However, the prevalences of anti‐islet autoantibodies in patients with Japanese type 1 diabetes are 60‐70% for GAD autoantibodies, 45‐50% for insulin autoantibodies (IAA), and 60‐65% for IA‐2 autoantibodies at disease onset, which are similar to those reported in Caucasian patients. With combinatorial analysis of these autoantibodies, 90% of patients express at least one of these autoantibodies and are classified as type 1A diabetics. There is a significant number of patients with latent autoimmune diabetes in adults (LADA) in Japan, and a high level of GAD autoantibodies has a high predictive value for future insulin deficiency in such patients. Recently, it has been reported that a group of extremely rapid‐onset patients presented with diabetic ketoacidosis and a low HbA1c level, called fulminant diabetes mellitus . Although they had severe hyperglycemia, these individuals lacked the expression of anti‐islet autoantibodies. With a nationwide survey, it was documented that fulminant type 1 diabetes accounts for ∼20% of the ketosis‐onset patients with type 1 diabetes in Japan. It is currently unknown whether the pathogenesis of fulminant type 1 diabetes is associated with autoimmune response to pancreatic islet β cells. Japanese patients with type 1 diabetes are clinically heterogeneous, and further investigations are required to clarify the underlying pathogenesis for each subgroup of type 1 diabetes.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom